GLP-1 Agonists List: A Complete Guide to GLP-1 Receptor Agonists by Class, Dose, and Use

GLP-1 Agonists List: A Complete Guide to GLP-1 Receptor Agonists by Class, Dose, and Use

By Dr. Onikepe Adegbola, MD PhD

Looking for a definitive GLP-1 agonists list? The class has expanded from a single diabetes drug to an entire therapeutic category spanning weight management, cardiovascular protection, and beyond. As of 2026, there are over a dozen GLP-1 receptor agonists either approved or in late-stage development — and the distinctions between them actually matter for clinical outcomes.

I've prescribed nearly every GLP-1 agonist on this list at some point in my career. Here's how they break down, what separates them, and how to think about which one might be right for you.

How GLP-1 Agonists Work

Before the list, the mechanism — because understanding how these drugs work helps you understand why different GLP-1 agonists produce different results.

GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after eating. It does several things simultaneously:

1. Stimulates insulin secretion — but only when blood sugar is elevated (glucose-dependent), which is why hypoglycemia is rare
2. Suppresses glucagon — reducing the liver's glucose output
3. Slows gastric emptying — food stays in your stomach longer, promoting satiety
4. Acts on brain appetite centers — reduces hunger signals and food reward responses in the hypothalamus

Natural GLP-1 has a half-life of about 2 minutes. It gets broken down by an enzyme called DPP-4 almost immediately. GLP-1 agonists are engineered versions that resist DPP-4 degradation — extending the action from minutes to hours or days. That's the pharmacological trick underlying the entire class.

The different drugs on the GLP-1 agonists list achieve this in different ways, which explains their varying potency, duration, and clinical effects.

The Complete GLP-1 Agonists List

First-Generation GLP-1 Agonists

These launched the class but are now largely superseded by newer agents for weight management.

Exenatide (Byetta, Bydureon)

• FDA approval: 2005 (Byetta), 2012 (Bydureon)
• Dosing: Twice daily (Byetta) or once weekly (Bydureon)
• Indication: Type 2 diabetes
• Weight loss: Modest (2–4%)
• Notes: The first GLP-1 agonist approved. Based on exendin-4, a peptide originally found in Gila monster venom. Historical importance, but clinically outclassed.

Lixisenatide (Adlyxin)

• FDA approval: 2016
• Dosing: Once daily
• Indication: Type 2 diabetes
• Weight loss: Minimal (1–3%)
• Notes: Short-acting, primarily used in combination with insulin (Soliqua). Limited standalone use.

Second-Generation GLP-1 Agonists

Improved pharmacokinetics, longer duration, and greater clinical impact.

Liraglutide (Victoza, Saxenda)

• FDA approval: 2010 (Victoza), 2014 (Saxenda)
• Dosing: Once daily injection
• Indications: Type 2 diabetes (Victoza), weight management (Saxenda)
• Weight loss: 5–8% (Saxenda at 3.0mg)
• Notes: Was the gold standard before semaglutide. Still useful for adolescent obesity (Saxenda approved age 12+) and patients who need daily dosing for adherence reasons.

Dulaglutide (Trulicity)

• FDA approval: 2014
• Dosing: Once weekly injection
• Indication: Type 2 diabetes
• Weight loss: 3–5%
• Notes: Once the most prescribed GLP-1 worldwide. User-friendly autoinjector. Cardiovascular outcomes data from the REWIND trial showed benefit. Less weight loss than semaglutide, but well-tolerated.

Third-Generation: High-Efficacy GLP-1 Agonists

The drugs driving the current revolution in obesity treatment.

Semaglutide (Ozempic, Wegovy, Rybelsus)

• FDA approval: 2017 (Ozempic), 2021 (Wegovy), 2019 (Rybelsus)
• Dosing: Once weekly injection (Ozempic/Wegovy) or once daily oral tablet (Rybelsus)
• Indications: Type 2 diabetes, weight management, cardiovascular risk reduction
• Weight loss: 10–17% (injectable), 5–8% (oral 14mg)
• Notes: The most extensively studied GLP-1 agonist. SELECT trial showed 20% reduction in major cardiovascular events. Available in both injectable and oral forms.

Tirzepatide (Mounjaro, Zepbound)

• FDA approval: 2022 (Mounjaro), 2023 (Zepbound)
• Dosing: Once weekly injection
• Indications: Type 2 diabetes, weight management
• Weight loss: 15–22.5% (dose-dependent)
• Notes: Dual GIP/GLP-1 receptor agonist. Produces the highest weight loss of any approved medication. Often grouped with GLP-1 agonists though technically it's a dual agonist.

Next-Generation Pipeline Agents

Retatrutide (Eli Lilly) — Triple GLP-1/GIP/glucagon agonist. Phase 3. Up to 24.2% weight loss in Phase 2.

Survodutide (Boehringer Ingelheim) — Dual GLP-1/glucagon agonist. Phase 3 for obesity and MASH.

CagriSema (Novo Nordisk) — Semaglutide + cagrilintide (amylin analogue) combination. Phase 3. 22–25% weight loss.

Orforglipron (Eli Lilly) — Non-peptide oral GLP-1 agonist. Phase 3. Up to 14.7% weight loss. No injection, no strict dosing requirements.

Pemvidutide (Altimmune) — Dual GLP-1/glucagon agonist. Phase 2 showing promise for MASH and weight loss.

Comparing GLP-1 Agonists: What Actually Differs

Patients often assume all GLP-1 agonists are basically the same drug in different packaging. They're not. The differences that matter clinically:

Receptor Selectivity

Pure GLP-1 agonists (semaglutide, liraglutide, dulaglutide) activate only the GLP-1 receptor. Tirzepatide adds GIP receptor activation. Retatrutide adds glucagon. Each additional receptor activation changes the metabolic effects — more weight loss, different effects on liver fat, potentially different cardiovascular profiles.

Duration of Action

Short-acting agents (exenatide twice daily, lixisenatide) primarily affect post-meal glucose spikes by slowing gastric emptying. Long-acting agents (semaglutide, dulaglutide, tirzepatide) have sustained effects on both fasting and post-meal glucose, plus stronger central appetite suppression. For weight loss, long-acting agents are significantly more effective.

Individual Response Variation

Here's something that surprises many patients: two people on the same GLP-1 agonist at the same dose can have completely different outcomes. One loses 25% of body weight with minimal side effects. The other loses 8% with significant nausea. This isn't about effort or compliance — it's biology.

Genetic polymorphisms in the GLP-1 receptor, differences in gut microbiome composition, baseline metabolic health, and even body composition all influence response. We don't yet have reliable biomarkers to predict who will respond best to which agent. In practice, this means sometimes you try one GLP-1 agonist, it doesn't work well or isn't tolerated, and switching to another produces much better results.

I've had patients who failed semaglutide do excellently on tirzepatide, and vice versa. The mechanism of GIP receptor activation in tirzepatide seems to hit differently for some patients — perhaps related to individual GIP receptor expression patterns, though we're speculating. The point is: if your first GLP-1 agonist isn't working, that doesn't mean the class has failed you. It means you may need a different one.

GI Side Effect Management

No matter which GLP-1 agonist you use, GI side effects are the most common reason patients discontinue treatment. Nausea, bloating, constipation, and sometimes diarrhea affect 30–50% of users during dose titration. This is where supportive care matters. Digestive enzyme supplementation, adequate protein intake, and gut-gentle nutrition support can make the difference between tolerating your GLP-1 agonist long-term and stopping prematurely. The Casa de Sante GLP-1 supplement line addresses each of these challenges specifically.

The Future of the GLP-1 Agonists List

The current list of GLP-1 agonists will look very different in 5 years. The trend lines are clear:

More receptor targets. We're moving from single agonists (GLP-1 only) to dual (GLP-1/GIP, GLP-1/glucagon) to triple (GLP-1/GIP/glucagon) agonists. Each additional receptor target appears to add metabolic benefit — more weight loss, better liver fat reduction, improved cardiovascular markers. Retatrutide's triple-agonist approach may represent where the field is heading.

Oral delivery. Injectables dominate today, but the shift to oral formulations is inevitable. Orforglipron and higher-dose oral semaglutide will make GLP-1 treatment more accessible and less intimidating for patients reluctant about needles.

Combination therapies. CagriSema (semaglutide + cagrilintide) shows that combining mechanisms produces results approaching bariatric surgery — without surgery. Expect more combinations targeting different appetite and metabolic pathways simultaneously.

Broader indications. GLP-1 agonists are being studied for Alzheimer's disease, Parkinson's disease, MASH (liver disease), sleep apnea, addiction, and more. The list of what these drugs might treat is expanding as fast as the list of available molecules.

For patients, the practical implication is that if today's GLP-1 agonists don't work well enough or cause too many side effects, better options are on the way. And for those who are doing well on current medications, supporting the treatment with proper nutrition and digestive care remains the foundation of good outcomes.

Frequently Asked Questions

What is the difference between GLP-1 agonists and GLP-1 receptor agonists?

These terms are used interchangeably. "GLP-1 receptor agonist" is the technically precise pharmacological term — these drugs activate (agonize) the GLP-1 receptor. "GLP-1 agonist" is the common shorthand. Both refer to the same class of medications.

Which GLP-1 agonist has the fewest side effects?

There's no clear winner. Individual tolerance varies significantly, and the same patient who tolerates semaglutide poorly might do fine on tirzepatide (or vice versa). Generally, slower dose titration reduces side effects across all agents. Liraglutide's daily dosing allows for very gradual titration, which some patients find more tolerable. Dulaglutide is often described as the "gentlest" weekly option by patients, though data is limited for direct GI comparisons.

Are GLP-1 agonists safe long-term?

The class has substantial long-term safety data. Exenatide has been on the market since 2005. Liraglutide since 2010. Semaglutide has the most robust outcomes data, with the SELECT cardiovascular trial showing safety and benefit over 5 years. Tirzepatide's long-term safety data is still accruing. Known risks across the class include pancreatitis (rare), gallbladder disease, and thyroid C-cell tumors in rodent studies (not confirmed in humans). Overall, the risk-benefit profile is favorable for patients with obesity or Type 2 diabetes.

Can GLP-1 agonists be combined with other diabetes medications?

Yes. GLP-1 agonists are commonly combined with metformin, SGLT2 inhibitors, and basal insulin. They should not be combined with DPP-4 inhibitors (which work on a related pathway and add no benefit when a GLP-1 agonist is present) or with other GLP-1 agonists. Your endocrinologist or primary care physician will manage combination therapy based on your specific needs.